Combination Therapy for Rare Dermal Sarcoma Effective, Avoids Radical Surgery

OncologyONCOLOGY Vol 10 No 4
Volume 10
Issue 4

Combined treatment involving surgery and radiotherapy is a reasonable alternative to surgery alone in high-risk patients with dermato-fibrosarcoma protruberans (DFSP), Canadian researchers reported at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting.

Combined treatment involving surgery and radiotherapy is a reasonablealternative to surgery alone in high-risk patients with dermato-fibrosarcomaprotruberans (DFSP), Canadian researchers reported at the AmericanSociety for Therapeutic Radiology and Oncology (ASTRO) meeting.

Dermatofibrosarcoma protruberans is an uncommon, low-grade sarcomaof the dermis and subcutis. Primary surgery is the preferred treatment;however, wide surgical clearance in certain sites may result incosmetic and/or functional loss.

For their study, Brian O'Sullivan, MD, and his colleagues at thePrincess Margaret Hospital, Toronto, reviewed all 45 DFSP casesreferred to their radiation oncology department between August,1958, and March, 1994. The tumors originated in the extremitiesin 16 patients, the head and neck in 17 cases, and the torso in12.

They found that excellent control rates were achievable even inhigh-risk cases. Their results showed local control in 17 of 19such cases, for a rate of 89%.

Dr. O'Sullivan, associate professor of radiation oncology, Universityof Toronto, emphasized that surgery is the recommended initialapproach in all cases of DFSP, with the expectation that all caseswill be controlled with margins greater than or equal to 1 cm.

However, adjuvant radiotherapy should be considered for microscopicresiduum--especially in locations where cosmesis or function wouldbe compromised by radical surgery--and in select sites when therisk of recurrence is high and there is potential for significantmorbidity from tumor relapse or subsequent surgery.

In this retrospective study, this approach to microscopic residualdisease, yielded the same impressive extent of control evidentin other soft-tissue sarcomas, he noted.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content